Timmerman ReportUnclaimed
Host of The Long Run with Luke Timmerman.
Host, The Long Run with Luke Timmerman
1 Feed-stated
Counts Verified and Feed-stated credits: what a show's own feed states, or a confirmation backs. See the record
- Host
Claim this profile Add a creditIs this you? Claiming needs a free account. You sign in or join, then come straight back here.
This profile is unclaimed. PodSubs built it from public show feeds and credits. The person it is about has not reviewed it yet.
About
Timmerman hosts The Long Run with Luke Timmerman.
Written by PodSubs from Timmerman's credits.
PodCred record
PodCred is the verified record of where Timmerman has worked and appeared. These credits come from the shows' own feeds and wait for people who were there to confirm them.
Worked with Timmerman on a show? This is where you give them credit.
Shows they work on now
1 show
Is an appearance missing?
People get invited back because someone remembered they were great. If you heard this person on a show and it is not listed here, add it. Your memory might be the reason they get their next invitation.
No account needed. Anyone can give a credit.
Experience, education, skills, and recommendations start empty. They fill in when Timmerman claims this profile.
Recommendations
No recommendations for Timmerman yet.
Recommendations open once Timmerman claims the profile.
Recent episodes
From the shows they work on now
Ep214: Shana Kelley on a Wearable Continuous Immune Monitor
The Long Run with Luke Timmerman
Shana Kelley, a professor of chemistry at Northwestern University and president of the Chan Zuckerberg Biohub Chicago, on developing a wearable continuous immune monitor.
Ep213: Daphne Koller on The Moment in AI Drug Discovery
The Long Run with Luke Timmerman
Daphne Koller, founder and CEO of South San Francisco-based Insitro, on the moment in AI drug discovery.
Ep212: Tim Shannon on Creating Targeted Protein Degraders as Medicines
The Long Run with Luke Timmerman
Tim Shannon is a general partner at Canaan Partners, and a founding executive at a pair of targeted protein degrader companies -- Arvinas and Halda Therapeutics.
Ep211: Ardem Patapoutian on Touch, Pain & New Discoveries in Neuroscience
The Long Run with Luke Timmerman
Arden Patapoutian, professor of neuroscience at Scripps Research and Howard Hughes Medical Institute, on new discoveries in neuroscience related to our sense of touch, pain, and more.
Ep210: Cameron Turtle on Long-Lasting Antibodies for Immune Disorders
The Long Run with Luke Timmerman
Cameron Turtle, CEO of Waltham, Mass.-based Spyre Therapeutics, on developing long-lasting antibodies for immune disorders.
Ep209: Mathai Mammen on Developing Drugs Against Undruggable Targets
The Long Run with Luke Timmerman
Mathai Mammen, CEO of Cambridge, Mass.-based Parabilis Medicine, on developing alpha helical peptide molecules against hard targets of disease.
Ep208: Gary Nabel on Developing a Vaccine for Epstein-Barr Virus
The Long Run with Luke Timmerman
Gary Nabel, CEO of Weston, Mass.-based ModeX Therapeutics, on developing a vaccine for Epstein-Barr Virus.
Ep207: Jason Coloma on Genetic Medicines for Kidney Diseases
The Long Run with Luke Timmerman
Jason Coloma, CEO of South San Francisco-based Maze Therapeutics, on developing small molecule drugs based on human genetics for kidney diseases.
Ep206: Lyn Baranowski on Inhalable Medicines for Severe Lung Diseases
The Long Run with Luke Timmerman
Lyn Baranowski, CEO of Boston-based Avalyn Pharma, on developing inhalable medicines for severe lung diseases.
Ep205: Heather Turner on a Schizophrenia Drug Patients Can Stick With
The Long Run with Luke Timmerman
Heather Turner, CEO of New York-based LB Pharma, on developing a new schizophrenia drug designed to better cross the blood-brain barrier, be dosed once daily, and make it easier for patients to take long term.
